Oct4 Antibody [K18A18]

Catalog No.: F2518

For research use only.

    Application: Reactivity:

    Usage Information

    Dilution
    1:10000
    1:30
    1:250
    1:110
    1:60
    8 µg per 107 cells
    Application
    WB, IP, IHC, IF, FCM, ChIP
    Reactivity
    Human, Mouse
    Source
    Rabbit Monoclonal Antibody
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW
    38kDa

    Datasheet & SDS

    Biological Description

    Specificity
    Oct4 Antibody [K18A18] detects endogenous levels of total Oct4 protein.
    Clone
    K18A18
    Synonym(s)
    OCT3; OCT4; OTF3; POU5F1; Octamer-binding protein 3; Octamer-binding protein 4; Octamer-binding transcription factor 3; Oct-3; Oct-4; OTF-3
    Background
    Oct4 (also known as Oct3/4, OTF3, or NF-A3) is a POU domain-containing transcription factor encoded by the Pou5f1 gene (human chromosome 6, mouse chromosome 17) and is a master regulator of pluripotency. Structurally, it is a ~352 amino acid protein (with human isoforms Oct4A and Oct4B generated by alternative splicing) that contains an N-terminal transactivation domain, a central POU-specific DNA-binding domain, a POU homeodomain, and a C-terminal transactivation domain. Oct4 is expressed in early embryos, embryonic stem (ES) cells, embryonic germ cells, and embryonic carcinoma cells, where its nuclear localization marks pluripotency; expression is later restricted to primordial germ cells and is normally silenced in differentiated somatic tissues. Functionally, Oct4 binds to octamer motifs (ATGCAAAT) in regulatory regions to activate or repress target genes, acting in concert with Sox2 and Nanog to maintain self-renewal, suppress differentiation, and regulate lineage specification. Its dosage-sensitive “rheostat” activity ensures stemness at defined levels, while altered expression drives differentiation toward trophoblast or endodermal lineages. Beyond development, Oct4 is crucial for somatic cell reprogramming into induced pluripotent stem cells and is aberrantly re-expressed in cancer stem cells, where it contributes to tumor initiation, therapy resistance, and relapse.
    References
    • https://pubmed.ncbi.nlm.nih.gov/25232507/

    Tech Support

    Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

    Handling Instructions

    Tel: +1-832-582-8158 Ext:3
    If you have any other enquiries, please leave a message.

    * Indicates a Required Field

    Please enter your name.
    Please enter your email. Please enter a valid email address.
    Please write something to us.